Fintel reports that on April 24, 2024, HSBC upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Reduce to Hold.

Analyst Price Forecast Suggests 29.03% Upside

As of April 17, 2024, the average one-year price target for Gilead Sciences is 86.54. The forecasts range from a low of 69.69 to a high of $127.05. The average price target represents an increase of 29.03% from its latest reported closing price of 67.07.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Gilead Sciences is 26,909MM, a decrease of 0.76%. The projected annual non-GAAP EPS is 7.32.

What is the Fund Sentiment?

There are 2,997 funds or institutions reporting positions in Gilead Sciences. This is an increase of 59 owner(s) or 2.01% in the last quarter. Average portfolio weight of all funds dedicated to GILD is 0.45%, an increase of 8.45%. Total shares owned by institutions increased in the last three months by 0.45% to 1,278,686K shares. The put/call ratio of GILD is 0.83, indicating a bullish outlook.

What are Other Shareholders Doing?

Capital World Investors holds 83,364K shares representing 6.69% ownership of the company. In its prior filing, the firm reported owning 81,721K shares , representing an increase of 1.97%. The firm decreased its portfolio allocation in GILD by 1.00% over the last quarter.

Capital Research Global Investors holds 59,657K shares representing 4.78% ownership of the company. In its prior filing, the firm reported owning 57,914K shares , representing an increase of 2.92%. The firm decreased its portfolio allocation in GILD by 0.51% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 39,137K shares representing 3.14% ownership of the company. In its prior filing, the firm reported owning 38,798K shares , representing an increase of 0.87%. The firm decreased its portfolio allocation in GILD by 2.55% over the last quarter.

AMECX - INCOME FUND OF AMERICA holds 34,765K shares representing 2.79% ownership of the company. In its prior filing, the firm reported owning 34,435K shares , representing an increase of 0.95%. The firm decreased its portfolio allocation in GILD by 7.05% over the last quarter.

Dodge & Cox holds 33,295K shares representing 2.67% ownership of the company. In its prior filing, the firm reported owning 33,534K shares , representing a decrease of 0.72%. The firm increased its portfolio allocation in GILD by 1.09% over the last quarter.

Gilead Sciences Background Information
(This description is provided by the company.)

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the Southern United States. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.